Switch theme
Sign up to access all valuation multiples
Jiangsu Wuzhong Pharmaceutical Development Co Ltd is a China-based company. It develops, produces and sells medicines while engages in real estate development.
1994
2.6K+
LTM Revenue $362M
LTM EBITDA $29.4M
$528M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Jiangsu Wuzhong Pharmaceutical has a last 12-month revenue of $362M and a last 12-month EBITDA of $29.4M.
In the most recent fiscal year, Jiangsu Wuzhong Pharmaceutical achieved revenue of $309M and an EBITDA of $7.0M.
Jiangsu Wuzhong Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Jiangsu Wuzhong Pharmaceutical valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $309M | $341M | XXX | XXX | XXX |
| Gross Profit | $70.5M | $79.9M | XXX | XXX | XXX |
| Gross Margin | 23% | 23% | XXX | XXX | XXX |
| EBITDA | $7.0M | $21.3M | XXX | XXX | XXX |
| EBITDA Margin | 2% | 6% | XXX | XXX | XXX |
| Net Profit | $3.1M | -$10.5M | XXX | XXX | XXX |
| Net Margin | 1% | -3% | XXX | XXX | XXX |
| Net Debt | $21.0M | $8.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Jiangsu Wuzhong Pharmaceutical's stock price is CNY 5 (or $1).
Jiangsu Wuzhong Pharmaceutical has current market cap of CNY 3.5B (or $483M), and EV of CNY 3.8B (or $528M).
See Jiangsu Wuzhong Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $528M | $483M | XXX | XXX | XXX | XXX | $0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Jiangsu Wuzhong Pharmaceutical has market cap of $483M and EV of $528M.
Jiangsu Wuzhong Pharmaceutical's trades at 1.5x LTM EV/Revenue multiple, and 18.0x LTM EBITDA.
Analysts estimate Jiangsu Wuzhong Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Jiangsu Wuzhong Pharmaceutical and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $528M | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | 24.8x | XXX | XXX | XXX |
| P/E | 48.8x | XXX | XXX | XXX |
| P/E/Growth | 0.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpJiangsu Wuzhong Pharmaceutical's NTM/LTM revenue growth is 19%
Jiangsu Wuzhong Pharmaceutical's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $30K for the same period.
Over next 12 months, Jiangsu Wuzhong Pharmaceutical's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Jiangsu Wuzhong Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Jiangsu Wuzhong Pharmaceutical and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 203% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 25% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $30K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 16% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 25% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jiangsu Wuzhong Pharmaceutical acquired XXX companies to date.
Last acquisition by Jiangsu Wuzhong Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Jiangsu Wuzhong Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Jiangsu Wuzhong Pharmaceutical founded? | Jiangsu Wuzhong Pharmaceutical was founded in 1994. |
| Where is Jiangsu Wuzhong Pharmaceutical headquartered? | Jiangsu Wuzhong Pharmaceutical is headquartered in China. |
| How many employees does Jiangsu Wuzhong Pharmaceutical have? | As of today, Jiangsu Wuzhong Pharmaceutical has 2.6K+ employees. |
| Is Jiangsu Wuzhong Pharmaceutical publicy listed? | Yes, Jiangsu Wuzhong Pharmaceutical is a public company listed on SHG. |
| What is the stock symbol of Jiangsu Wuzhong Pharmaceutical? | Jiangsu Wuzhong Pharmaceutical trades under 600200 ticker. |
| When did Jiangsu Wuzhong Pharmaceutical go public? | Jiangsu Wuzhong Pharmaceutical went public in 1999. |
| Who are competitors of Jiangsu Wuzhong Pharmaceutical? | Similar companies to Jiangsu Wuzhong Pharmaceutical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Jiangsu Wuzhong Pharmaceutical? | Jiangsu Wuzhong Pharmaceutical's current market cap is $483M |
| What is the current revenue of Jiangsu Wuzhong Pharmaceutical? | Jiangsu Wuzhong Pharmaceutical's last 12-month revenue is $362M. |
| What is the current EBITDA of Jiangsu Wuzhong Pharmaceutical? | Jiangsu Wuzhong Pharmaceutical's last 12-month EBITDA is $29.4M. |
| What is the current EV/Revenue multiple of Jiangsu Wuzhong Pharmaceutical? | Current revenue multiple of Jiangsu Wuzhong Pharmaceutical is 1.5x. |
| What is the current EV/EBITDA multiple of Jiangsu Wuzhong Pharmaceutical? | Current EBITDA multiple of Jiangsu Wuzhong Pharmaceutical is 18.0x. |
| What is the current revenue growth of Jiangsu Wuzhong Pharmaceutical? | Jiangsu Wuzhong Pharmaceutical revenue growth between 2023 and 2024 was 11%. |
| Is Jiangsu Wuzhong Pharmaceutical profitable? | Yes, Jiangsu Wuzhong Pharmaceutical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
